Alps ETF Trust - Alps REIT Dividend Dogs ETF(NYSEMKT) GRI

Market CapN/A

Since IPO (2008)+96%

5 Year+12%

1 Year+19%

1 Month-2%

N/A

Alps ETF Trust - Alps REIT Dividend Dogs ETF last closing stock price
Metric	Price	Date
Last close	USD 41.34	2026-08-26

Alps ETF Trust - Alps REIT Dividend Dogs ETF stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.74%	USD 41.04	2026-08-19
1 month	-2.02%	USD 42.19	2026-07-27
3 month	+2.55%	USD 40.31	2026-05-28
Year to date	+18.85%	USD 34.79	2025-12-31
1 year	+18.74%	USD 34.82	2025-08-26
3 year	+41.53%	USD 29.21	2023-08-24
5 year	+11.67%	USD 37.02	2021-08-27
Since inception	+96.21%	USD 21.07	2008-05-09

Alps ETF Trust - Alps REIT Dividend Dogs ETF Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$9.66M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 13, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 13, 2026

GRI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alps ETF Trust - Alps REIT Dividend Dogs ETF

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune disorders. The company is advancing its lead product candidate, GRI-0621, which is currently in phase IIa clinical trials for severe fibrotic lung diseases.

Products and Services

GRI-0621: Oral inhibitor for type 1 Natural Killer T cells
GRI-0803: Oral agonist for type 2 Natural Killer T cells in preclinical development
Proprietary library of over 500 compounds targeting immune responses

Growth Outlook

Phase IIa trials for GRI-0621 could lead to significant market opportunities
Expansion into autoimmune disorder treatments with GRI-0803
Strong pipeline with over 500 proprietary compounds enhances growth potential

Financial Highlights

Cash and cash equivalents of $10.9 million as of June 30, 2026
Current ratio of 10.30 indicates strong liquidity position
Net income of -$1.64 million for Q2 2026, reflecting ongoing R&D investments

GRI Bio, Inc. is strategically positioned in the biotechnology sector, focusing on innovative therapies that address unmet medical needs. The company's lead candidate, GRI-0621, is undergoing critical clinical trials, which could pave the way for future revenue streams. With a robust pipeline and significant cash reserves, GRI Bio is poised for potential growth in the biopharmaceutical landscape. The current financial metrics indicate a strong liquidity position, allowing for continued investment in research and development.

AI Generated • Aug 19, 2026

Industry

Capital Markets

Sector

Financials

Headquarters

La Jolla, CA 92037, US

GRI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-134.03%

Return on Capital

-197.02%

Return on Assets

-84.88%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$9.68M

EBITDA

-$9.68M

Operating Cash Flow

-$10.42M

Capital Expenditure

-$3.00K

Free Cash Flow

-$10.42M

Cash & ST Invst.

$10.95M

Total Debt

$44.00K

Alps ETF Trust - Alps REIT Dividend Dogs ETF Performance Analysis

Alps ETF Trust - Alps REIT Dividend Dogs ETF sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-10-31	N/A
Q4	2026-01-31	N/A
Q1	2026-04-30	N/A
Q2	2026-06-30	N/A

Alps ETF Trust - Alps REIT Dividend Dogs ETF sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-10-31	2.3%
Q4	2026-01-31	85.1%
Q1	2026-04-30	69.9%
Q2	2026-06-30	43.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$1.64M

+43.2%

EBITDA

-$1.65M

+43.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$10.95M

+113.7%

Total Debt

$44.00K

-54.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$44.00K

-15.4%

Return on Assets

-84.88%

N/A

Return on Invested Capital

-94.16%

N/A

Free Cash Flow

-$1.45M

+54.3%

Operating Cash Flow

-$1.45M

+54.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CNSPCNS Pharmaceuticals, Inc.

CNSPCNS Pharmaceuticals, Inc.$5.52+1.42%

JAGXJaguar Health, Inc.

JAGXJaguar Health, Inc.$0.87-5.92%

SILOSilo Pharma, Inc.

SILOSilo Pharma, Inc.$2.54+1.60%

BDRXBiodexa Pharmaceuticals Plc

BDRXBiodexa Pharmaceuticals Plc$0.90-7.91%

ABPAbpro Corporation

ABPAbpro Corporation$0.52+0.00%

INMInMed Pharmaceuticals Inc.

INMInMed Pharmaceuticals Inc.$1.43+0.00%

SXTP60 Degrees Pharmaceuticals, Inc.

SXTP60 Degrees Pharmaceuticals, Inc.$1.06-1.85%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$227.98+0.09%

INTCIntel

INTCIntel$92.09+0.04%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.78+0.02%

ONDSOndas

ONDSOndas$8.75+0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.31+0.05%

PATHUiPath

PATHUiPath$18.33+0.09%

NOKNokia

NOKNokia$10.59+0.02%

Questions About GRI

What is the current price of Alps ETF Trust - Alps REIT Dividend Dogs ETF?

Alps ETF Trust - Alps REIT Dividend Dogs ETF is trading at N/A per share.

What is the 52-week range for Alps ETF Trust - Alps REIT Dividend Dogs ETF?

Over the past 52 weeks, Alps ETF Trust - Alps REIT Dividend Dogs ETF has traded between N/A and N/A.

How much debt does Alps ETF Trust - Alps REIT Dividend Dogs ETF have?

Alps ETF Trust - Alps REIT Dividend Dogs ETF total debt is unavailable.

How much cash does Alps ETF Trust - Alps REIT Dividend Dogs ETF have on hand?

Alps ETF Trust - Alps REIT Dividend Dogs ETF does not have cash on hand data available.

What is Alps ETF Trust - Alps REIT Dividend Dogs ETF’s dividend yield?

Alps ETF Trust - Alps REIT Dividend Dogs ETF does not currently have a dividend yield.

Alps ETF Trust - Alps REIT Dividend Dogs ETF(NYSEMKT) GRI

Alps ETF Trust - Alps REIT Dividend Dogs ETF Financials at a Glance

GRI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Alps ETF Trust - Alps REIT Dividend Dogs ETF

GRI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Alps ETF Trust - Alps REIT Dividend Dogs ETF Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GRI

What is the current price of Alps ETF Trust - Alps REIT Dividend Dogs ETF?

What is the 52-week range for Alps ETF Trust - Alps REIT Dividend Dogs ETF?

How much debt does Alps ETF Trust - Alps REIT Dividend Dogs ETF have?

How much cash does Alps ETF Trust - Alps REIT Dividend Dogs ETF have on hand?

What is Alps ETF Trust - Alps REIT Dividend Dogs ETF’s dividend yield?

Premium Investing Services